CYduct Diagnostics, Inc.
CYDX · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.10 | -0.23 | 0.31 |
| FCF Yield | -2.17% | -3.03% | -0.83% | -1.32% |
| EV / EBITDA | -17.68 | -19.77 | -33.80 | -43.32 |
| Quality | ||||
| ROIC | 5.01% | 3.99% | 5.55% | 4.53% |
| Gross Margin | 65.84% | 68.93% | 70.10% | 57.26% |
| Cash Conversion Ratio | 0.02 | 0.20 | 0.27 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.02% | -12.77% | -13.23% | -9.89% |
| Free Cash Flow Growth | 4.64% | -3.70% | 35.95% | 20.99% |
| Safety | ||||
| Net Debt / EBITDA | -7.10 | -9.15 | -6.50 | -8.19 |
| Interest Coverage | -7.79 | -5.83 | -8.78 | -6.92 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.48 | 0.31 | 0.91 |
| Cash Conversion Cycle | -2,512.48 | -1,896.58 | -3,325.39 | -800.79 |